Incyte (INCY) Q4 Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Incyte (INCY) PT Raised to $175 at BMO Capital; 'We Like Risk/Reward Heading into ECHO-301'
February 15, 2018 3:06 PM ESTBMO Capital raised its price target on Incyte (NASDAQ: INCY) to $175.00 (from $172.00) while maintaining an Outperform rating.
Analyst M. Ian Somaiya commented, "Despite strong fundamentals and a rich pipeline, investor focus remains singularly on the upcoming epacadostat Phase 3 melanoma data (ECHO-301), with positive... More
UPDATE: SunTrust Robinson Humphrey Reiterates Bullish View on Incyte (INCY)
February 15, 2018 2:35 PM EST(Updated - February 15, 2018 2:50 PM EST)
(updated to expand analyst comment)
SunTrust Robinson Humphrey analyst Peter Lawson reiterated a Buy rating and $155 price target on Incyte (NASDAQ: INCY)
Lawson calls Q4 "Minor Jakafi Miss, but Focus on Epacadostat Readouts in 2018." The... More
